The role of ACKR3 in breast, lung, and brain cancer

Maria Neves; Amos Fumagalli; Jelle van den Bor; Philippe Marin; Martine J. Smit; Federico Mayor

doi:10.1124/mol.118.115279

The role of ACKR3 in breast, lung, and brain cancer

Maria Neves, Amos Fumagalli, Jelle van den Bor, Philippe Marin, Martine J. Smit, Federico Mayor^*

^*Corresponding author for this work

AIMMS

Research output: Contribution to Journal › Article › Academic › peer-review

56 Downloads (Pure)

Abstract

Recent reports regarding the significance of chemokine receptors in disease have put a spotlight on atypical chemokine receptor 3 (ACKR3). This atypical chemokine receptor is overexpressed in numerous cancer types and has been involved in the modulation of tumor cell proliferation and migration, tumor angiogenesis, or resistance to drugs, thus contributing to cancer progression and metastasis occurrence. Here, we focus on the clinical significance and potential mechanisms underlying the pathologic role of ACKR3 in breast, lung, and brain cancer and discuss its possible relevance as a prognostic factor and potential therapeutic target in these contexts.

Original language	English
Pages (from-to)	819-825
Number of pages	7
Journal	Molecular pharmacology
Volume	96
Issue number	6
DOIs	https://doi.org/10.1124/mol.118.115279
Publication status	Published - Dec 2019

Bibliographical note

Available online 2 January 2025.

Funding

This work was supported by the European Union H2020-MSCA Program [Grant Agreement 64183], ONCORNET to P.M., M.J.S., and F.M.; Ministerio de Economía, Industria y Competitividad of Spain [Grant SAF2017-84125-R] to F.M.; CIBERCV-Instituto de Salud Carlos III, Spain [Grant CB16/11/00278] to F.M.; cofunded with European FEDER contribution, Comunidad de Madrid [B2017/BMD-3671-INFLAMUNE] to F.M.; Fundación Ramón Areces to F.M.; Portuguese Foundation for Science and Technology [Grant SFRH/BD/136574/ 2018] to M.N.; Netherlands Organization for Scientific Research NWO: Vici [Grant 016.140.657] to M.J.S.; and grants from CNRS, INSERM, Université de Montpellier and Fondation pour la Recherche Médicale (FRM) to P.M. 1A.F. and J.v.d.B. contributed equally to this work. https://doi.org/10.1124/mol.118.115279.

Funders	Funder number
Institut national de la santé et de la recherche médicale
Centre National de la Recherche Scientifique
Fondation pour la Recherche Médicale
Federación Española de Enfermedades Raras
ONCORNET
Fundación Ramón Areces
Université de Montpellier
Horizon 2020 Framework Programme	641833
European Union H2020-MSCA Program	64183
Ministerio de Asuntos Económicos y Transformación Digital, Gobierno de España	SAF2017-84125-R
Comunidad de Madrid	B2017/BMD-3671-INFLAMUNE
Netherlands Organization for Scientific Research NWO	016.140.657
Fundação para a Ciência e a Tecnologia	SFRH/BD/136574/ 2018
CIBERCV-Instituto de Salud Carlos III	CB16/11/00278

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Access to Document

10.1124/mol.118.115279

The role of ACKR3 in breast, lung, and brain cancerFinal published version, 487 KBLicence: Article 25fa Dutch Copyright Act

Persistent URL (handle)

Persistent link

Cite this

@article{505a579a05424cf2a938406c5b9c1b82,

title = "The role of ACKR3 in breast, lung, and brain cancer",

abstract = "Recent reports regarding the significance of chemokine receptors in disease have put a spotlight on atypical chemokine receptor 3 (ACKR3). This atypical chemokine receptor is overexpressed in numerous cancer types and has been involved in the modulation of tumor cell proliferation and migration, tumor angiogenesis, or resistance to drugs, thus contributing to cancer progression and metastasis occurrence. Here, we focus on the clinical significance and potential mechanisms underlying the pathologic role of ACKR3 in breast, lung, and brain cancer and discuss its possible relevance as a prognostic factor and potential therapeutic target in these contexts.",

author = "Maria Neves and Amos Fumagalli and \{van den Bor\}, Jelle and Philippe Marin and Smit, \{Martine J.\} and Federico Mayor",

note = "Available online 2 January 2025.",

year = "2019",

month = dec,

doi = "10.1124/mol.118.115279",

language = "English",

volume = "96",

pages = "819--825",

journal = "Molecular pharmacology",

issn = "0026-895X",

publisher = "Elsevier Inc.",

number = "6",

}

TY - JOUR

T1 - The role of ACKR3 in breast, lung, and brain cancer

AU - Neves, Maria

AU - Fumagalli, Amos

AU - van den Bor, Jelle

AU - Marin, Philippe

AU - Smit, Martine J.

AU - Mayor, Federico

N1 - Available online 2 January 2025.

PY - 2019/12

Y1 - 2019/12

N2 - Recent reports regarding the significance of chemokine receptors in disease have put a spotlight on atypical chemokine receptor 3 (ACKR3). This atypical chemokine receptor is overexpressed in numerous cancer types and has been involved in the modulation of tumor cell proliferation and migration, tumor angiogenesis, or resistance to drugs, thus contributing to cancer progression and metastasis occurrence. Here, we focus on the clinical significance and potential mechanisms underlying the pathologic role of ACKR3 in breast, lung, and brain cancer and discuss its possible relevance as a prognostic factor and potential therapeutic target in these contexts.

AB - Recent reports regarding the significance of chemokine receptors in disease have put a spotlight on atypical chemokine receptor 3 (ACKR3). This atypical chemokine receptor is overexpressed in numerous cancer types and has been involved in the modulation of tumor cell proliferation and migration, tumor angiogenesis, or resistance to drugs, thus contributing to cancer progression and metastasis occurrence. Here, we focus on the clinical significance and potential mechanisms underlying the pathologic role of ACKR3 in breast, lung, and brain cancer and discuss its possible relevance as a prognostic factor and potential therapeutic target in these contexts.

UR - https://www.scopus.com/pages/publications/85075072616

UR - https://www.scopus.com/inward/citedby.url?scp=85075072616&partnerID=8YFLogxK

U2 - 10.1124/mol.118.115279

DO - 10.1124/mol.118.115279

M3 - Article

C2 - 30745320

AN - SCOPUS:85075072616

SN - 0026-895X

VL - 96

SP - 819

EP - 825

JO - Molecular pharmacology

JF - Molecular pharmacology

IS - 6

ER -

The role of ACKR3 in breast, lung, and brain cancer

Abstract

Bibliographical note

Funding

UN SDGs

Access to Document

Persistent URL (handle)

Other files and links

Fingerprint

Cite this